Ramelteon
Ramelteon, Rozerem (ramelteon) is a small molecule pharmaceutical. Ramelteon was first approved as Rozerem on 2005-07-22. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Ramelteon, Rozerem
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sleep initiation and maintenance disorders | — | D007319 | F51.01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
78 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 2 | 4 | 15 | 8 | 3 | 32 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 4 | 1 | — | 5 |
| Sleep wake disorders | D012893 | — | G47 | — | 2 | — | 1 | — | 3 |
| Depression | D003863 | — | F33.9 | — | — | 2 | 1 | — | 3 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 2 | 1 | — | 3 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | 1 | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | 1 | — | 2 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | — | 1 | — | 2 |
| Obstructive lung diseases | D008173 | — | — | — | 1 | — | 1 | — | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 1 | 1 | — | 2 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parasomnias | D020447 | — | G47.5 | — | 1 | 1 | — | — | 2 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | 1 | — | — | 2 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 1 | 1 | — | — | 2 |
| Apnea | D001049 | — | R06.81 | — | 1 | 1 | — | — | 2 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
| Dyssomnias | D020920 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | 1 | — | — | — | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | 1 | — | — | — | 1 |
| Circadian rhythm sleep disorders | D020178 | — | G47.2 | — | 1 | — | — | — | 1 |
| Intrinsic sleep disorders | D020919 | — | F51.03 | — | 1 | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinsonian disorders | D020734 | — | G20.C | — | — | — | — | 1 | 1 |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | — | — | — | 1 | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 1 | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | — | — | 1 | 1 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ramelteon |
| INN | ramelteon |
| Description | N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide is a member of indanes. |
| Classification | Small molecule |
| Drug class | selective melatonin receptor agonist |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3 |
Identifiers
| PDB | — |
| CAS-ID | 196597-26-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1218 |
| ChEBI ID | — |
| PubChem CID | 208902 |
| DrugBank | DB00980 |
| UNII ID | 901AS54I69 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Ramelteon
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,980 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,778 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use